iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray

Launched by SECOND AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY · Jun 17, 2017

Keywords

ClinConnect Summary

This clinical trial is studying a new tool called iCAGES, which helps doctors tailor treatment for patients with advanced lung cancer and other serious cancers. The goal is to see if using this tool leads to better outcomes, such as longer time without disease progression and improved overall survival, compared to standard treatment methods or another approach based on immunohistochemistry (IHC). The trial is currently looking for participants and aims to understand if this precision therapy can enhance the quality of life for cancer patients.

To be eligible for the trial, participants must be between 18 and 70 years old, have a confirmed diagnosis of advanced or recurring lung cancer, and be willing to provide written consent. Unfortunately, individuals with a history of other cancers, those who are pregnant or breastfeeding, or those with certain serious health issues cannot take part. Participants can expect to receive personalized treatment based on the iCAGES tool, along with regular assessments to monitor their progress throughout the study. This trial is an opportunity to explore new, potentially more effective treatment options for advanced cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pathological and clinical diagnosis of recurrence / metastatic lung cancer or other advanced cancers.
• • There are PACS images available at the Second Affiliated Hospital of Guangzhou Medical University and the collaborated Hospitals.
• • The patient is informed consent and signed a written consent.
• Exclusion Criteria:
• • Age \> 70 or \<18 years old.
• • Previous history of malignant tumors.
• • Pregnant or lactating female patients.
• • Any serious concomitant disease that is expected to have an adverse effect on prognosis, including the heart disease that treatment is required, unsatisfactory controlled diabetes and psychiatric disorders.